An Open-Label Prospective, Non-Comparative Study to Evaluate the Subjective Experiences Upon Transition to Paliperidone Extended Release(ER) in Subjects With Schizophrenia.
Phase of Trial: Phase IV
Latest Information Update: 04 Jul 2014
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms PASS
- Sponsors Janssen
- 10 Jun 2017 Biomarkers information updated
- 10 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2012 Actual patient number changed from 27 to 388 as reported by ClinicalTrials.gov.